We, therefore, conclude that the loss of Tuba4a C-terminal polyglutamylation (Tuba4aΔpolyGlu) is sufficient to normalize the hyper-phosphorylation Tau phenotype, characteristic of the hTau tauopathy model51, in vivo. The gene discussed is MAPT; the disease is tauopathy.